FILE:JPM/JPM-8K-20080429172826.txt.gz
EVENTS:	Financial Statements and Exhibits
TEXT:
ITEM: Financial Statements and Exhibits
 
 
UNITED STATES
 
 
 
 
 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
 
 
 
 
Item 9.01.   Financial Statements and Exhibits
 
(d)  Exhibits
 
The following Exhibits are incorporated by reference into the Registration Statement on Form S-3ASR (333-130051) of JPMorgan Chase & Co. (the Registrant) as exhibits thereto and are filed as part of this Current Report.
 
 
 
2
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Dated: April 29, 2008
 
3
 
EXHIBIT INDEX
 
 
 
4
 
 

 
Exhibit 8.1
 
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1205 dated April 25, 2008 relating to Notes Linked to a Weighted Basket of Three Buffered Return Enhanced Components, Consisting of the Dow Jones EURO STOXX 50Index, the FTSE 100 Index and the TOPIX Index due May 18, 2009 (the Pricing Supplement) to product supplement no. 103-I dated October 19, 2007 relating to Notes Linked to a Basket of Return Enhanced Components (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.
 
 
 
 
 
 

 
Exhibit 8.2
 
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1206 dated April 25, 2008 relating to Buffered Return Enhanced Notes Linked to a Basket Consisting of the AMEX Hong Kong 30 Index, the FTSE/Xinhua China 25 Index, the Korea Stock Price Index 200, the MSCI Singapore Index and the MSCI Taiwan Index due May 14, 2009 (the Pricing Supplement) to product supplement no. 54-IV dated May 4, 2007 relating to Return Enhanced Notes Linked to a Weighted Basket Consisting of the AMEX Hong Kong 30 Index, the CECEEUR Index, the Dow Jones EURO STOXX 50 Index, the Dow Jones U.S. Real Estate Index, the FTSE 100 Index, the FTSE/Xinhua China 25 Index, the Korea Stock Price Index 200, the Kuala Lumpur Composite Index, the MSCI SingaporeIndex, the MSCI Taiwan Index, the Nikkei 225 Index, the Russell 2000 Index, the Russian Depositary Receipts Index, the S&P 500 Index, the S&P BRIC 40 Index, the Goldman Sachs Commodity Index Excess Return, the iShares MSCI Brazil Index Fund and the iShares MSCI Emerging Markets Index Fund (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
 
 
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.
 
 
 
 
 
 

 
Exhibit 8.3
 
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1207 dated April 25, 2008 relating to Buffered Return Enhanced Notes Linked to the S&P 500 Index due October 30, 2009 (the Pricing Supplement) to product supplement no. 18-I dated March 16, 2006 relating to Return Enhanced Notes Linked to the S&P 500 Index (the Product Supplement) to a prospectus supplement dated December 1, 2005 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.
 
 
 
 
 
 

 
Exhibit 8.4
 
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1208 dated April 25, 2008 relating to Buffered Return Enhanced Notes Linked to the S&P 500 Index due October 30, 2009 (the Pricing Supplement) to product supplement no. 18-I dated March 16, 2006 relating to Return Enhanced Notes Linked to the S&P 500 Index (the Product Supplement) to a prospectus supplement dated December 1, 2005 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.
 
 
 
 
 
 

 
Exhibit 8.5
 
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1209 dated April 25, 2008 relating to Buffered Return Enhanced Notes Linked to the MSCI EAFE Index due October 30, 2009 (the Pricing Supplement) to product supplement no. 39-IX dated March 31, 2008 relating to Return Enhanced Notes Linked to a Weighted Basket Consisting of the S&P 500 Index, the S&P BRIC 40 Index, the Nikkei 225 Index, the Dow Jones EURO STOXX 50 Index, the Dow Jones U.S. Real Estate Index, the Dow Jones  AIG Commodity Index, the FTSE 100 Index, the MSCI EAFE Index, the NASDAQ-100 Index, the Russell 1000 Growth Index, the Russell 1000 Value Index, the Russell 2000 Index, the iShares Dow Jones U.S. Real Estate Index Fund, the iShares MSCI Emerging Markets Index Fund, the SPDR S&P Homebuilders ETF, the Financial Select Sector SPDR Fund and the Vanguard Emerging Markets ETF (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
SM
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.
 
 
 
 
 
 

 
Exhibit 8.6
 
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1210 dated April 25, 2008 relating to Bearish Buffered Return Enhanced Notes Linked Inversely to the S&P 500 Index due October 31, 2008 (the Pricing Supplement) to product supplement no. 87-I dated July 10, 2007 relating to Bearish Return Enhanced Notes Linked Inversely to the S&P 500 Index (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.
 
 
 
 
 
 

 
Exhibit 8.7
 
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1211 dated April 25, 2008 relating to Principal Protected Dual Directional Notes Linked to a Weighted Basket Consisting of Three Commodities and Three Commodity Indices due October 31, 2012 (the Pricing Supplement) to product supplement no. 102-I dated October 15, 2007 relating to Principal Protected Dual Directional Notes Linked to a Weighted Basket Consisting of up to Thirteen Commodities and/or Five Commodity Indices, or Linked to Any One of the Foregoing (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Taxed as Contingent Payment Debt Instruments in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Taxed as Contingent Payment Debt Instruments in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.
 
 
 
 
 
 

 
Exhibit 8.8
 
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1212 dated April 25, 2008 relating to Buffered Return Enhanced Notes Linked to a Weighted Basket Consisting of the S&P 500 Index, the MSCI EAFE Index, the Russell 2000 Index and the iShares MSCI Emerging Markets Index Fund due April 30, 2013 (the Pricing Supplement) to product supplement no. 39-IX dated March 31, 2008 relating to Return Enhanced Notes Linked to a Weighted Basket Consisting of the S&P 500 Index, the S&P BRIC 40 Index, the Nikkei 225 Index, the Dow Jones EURO STOXX 50 Index, the Dow Jones U.S. Real Estate Index, the Dow Jones  AIG Commodity Index, the FTSE 100 Index, the MSCI EAFE Index, the NASDAQ-100 Index, the Russell 1000 Growth Index, the Russell 1000 Value Index, the Russell 2000 Index, the iShares Dow Jones U.S. Real Estate Index Fund, the iShares MSCI Emerging Markets Index Fund, the SPDR S&P Homebuilders ETF, the Financial Select Sector SPDR Fund and the Vanguard Emerging Markets ETF (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
SM
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.
 
 
 
 
 
 

 
Exhibit 8.9
 
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1213 dated April 25, 2008 relating to Principal Protected Dual Directional Knock-Out Notes Linked to the S&P 500 Index and the Russell 2000 Index due August 31, 2009 (the Pricing Supplement) to product supplement no. 114-I dated February 1, 2008 relating to Principal Protected Dual Directional Knock-Out Notes Linked to One or More of the Following Indices: the S&P 500Index, the Russell 2000 Index, the Nikkei 225 Index and the Dow Jones EURO STOXX 50 Index (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Treated as Contingent Payment Debt Instruments in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Treated as Contingent Payment Debt Instruments in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.
 
 
 
 
 
 

 
Exhibit 8.10
 
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1214 dated April 25, 2008 relating to Buffered Return Enhanced Notes Linked to an Equally Weighted Basket Consisting of the MSCI EAFE Index and the iShares MSCI Emerging Markets Index Fund due April 30, 2010 (the Pricing Supplement) to product supplement no. 39-IX dated March 31, 2008 relating to Return Enhanced Notes Linked to a Weighted Basket Consisting of the S&P 500 Index, the S&P BRIC 40 Index, the Nikkei 225 Index, the Dow Jones EURO STOXX 50 Index, the Dow Jones U.S. Real Estate Index, the Dow Jones  AIG Commodity Index, the FTSE 100 Index, the MSCI EAFE Index, the NASDAQ-100 Index, the Russell 1000 Growth Index, the Russell 1000 Value Index, the Russell 2000 Index, the iShares Dow Jones U.S. Real Estate Index Fund, the iShares MSCI Emerging Markets Index Fund, the SPDR S&P Homebuilders ETF, the Financial Select Sector SPDR Fund and the Vanguard Emerging Markets ETF (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
SM
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Tax Treatment in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Tax Treatment in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.
 
 
 
 
 
 

 
Exhibit 8.11
 
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1215 dated April 25, 2008 relating to Upside Auto Callable Reverse Exchangeable Notes due October 31, 2008 Each Linked to the Common Stock of a Different Single Reference Stock Issuer (the Pricing Supplement) to product supplement no. 108-I dated December 13, 2007 relating to Upside Auto Callable Reverse Exchangeable Notes Linked to the Common Stock of a Reference Stock Issuer (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Tax Treatment as a Unit Comprising a Put Option and a Deposit in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Tax Treatment as a Unit Comprising a Put Option and a Deposit in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.
 
 
 
 
 
 

 
Exhibit 8.12
 
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1216 dated April 25, 2008 relating to Return Enhanced Notes Linked to the NASDAQ-100 Index due May 8, 2009 (the Pricing Supplement) to product supplement no. 39-IX dated March 31, 2008 relating to Return Enhanced Notes Linked to a Weighted Basket Consisting of the S&P 500 Index, the S&P BRIC 40 Index, the Nikkei 225 Index, the Dow Jones EURO STOXX 50 Index, the Dow Jones U.S. Real Estate Index, the Dow Jones  AIG Commodity IndexSM, the FTSE 100 Index, the MSCI EAFE Index, the NASDAQ-100 Index, the Russell 1000 Growth Index, the Russell 1000 Value Index, the Russell 2000 Index, the iShares Dow Jones U.S. Real Estate Index Fund, the iShares MSCI Emerging Markets Index Fund, the SPDR S&P Homebuilders ETF, the Financial Select Sector SPDR Fund and the Vanguard Emerging Markets ETF (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations Capital Gains Tax Treatment, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
 
 in the Pricing Supplement
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations Capital Gains Tax Treatment.  By such consent we do not concede that we are an expert for the purposes of the Act.
 
 in the Pricing Supplement
 
 
 
 
 
 

 
Exhibit 8.13
 
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1217 dated April 25, 2008 relating to 4.0% (equivalent to 16.0% per annum) Reverse Exchangeable Notes due July 31, 2008 Linked to the Least Performing Common Stock of Bank of America Corporation, Citigroup Inc., The Goldman Sachs Group, Inc. and Merrill Lynch & Co., Inc. (the Pricing Supplement) to product supplement no. 68-I dated February 7, 2007 relating to Reverse Exchangeable Notes Linked to the Least Performing Common Stock of Two or More Reference Stock Issuers (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Tax Treatment as a Unit Comprising a Put Option and a Deposit in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Tax Treatment as a Unit Comprising a Put Option and a Deposit in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.
 
 
 
 
 
 

 
Exhibit 8.14
 
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1218 dated April 25, 2008 relating to Return Enhanced Notes Linked to an Equally Weighted Basket of 18 Common Stocks due October 30, 2009 (the Pricing Supplement) to product supplement no. 133-I dated April 25, 2008 relating to Return Enhanced Notes Linked to a Basket of Common Stocks (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations Capital Gains Tax Treatment, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
 
 in the Pricing Supplement
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations Capital Gains Tax Treatment.  By such consent we do not concede that we are an expert for the purposes of the Act.
 
 in the Pricing Supplement
 
 
 
 
 
 


